News
Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...
17h
MedPage Today on MSNOnce-Monthly Oral PrEP Option Appears Safe, Tolerable in Adults at Low Risk of HIVThe investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to ...
9h
The Star on MSNResearchers uncover new treatment modes for older people with HIVExperts have proposed new treatment modes for older people with HIV. The new treatment does not cause the health-threatening ...
The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...
For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...
Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...
Long-acting injectable PrEP may improve access, protection and adherence, especially for young people and pregnant women, according to Hasina Subedar, a senior technical advisor at South Africa’s ...
The 2024 meeting of the International AIDS Society (IAS), which is being held in Munich this week, began with the announcement of another curative bone marrow transplant. The new case brings the total ...
The International AIDS Society (IAS) on Sunday called on President Trump to increase funding for AIDS research, warning that his proposed spending cuts could cause deaths. IAS president Linda-Gail ...
After a five-month battle with leukemia, the first known person to be cured of HIV has died of cancer, according to the International AIDS Society. Timothy Ray Brown, also known as “the Berlin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results